Determination of N-acetylation phenotyping in a Greek population using caffeine as a metabolic probe

被引:17
作者
Asprodini, EK [1 ]
Zifa, E [1 ]
Papageorgiou, I [1 ]
Benakis, A [1 ]
机构
[1] Univ Thessalia, Dept Med, Pharmacol Lab, Larissa, Greece
关键词
N-acetylation; pharmacogenetics; phenotyping; human; polymorphism;
D O I
10.1007/BF03190002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Studies of isoniazid, the well known antituberculosis drug, have revealed that N-acetylation polymorphism, is of great clinical importance. In humans, N-acetylation is one of the most important pathways in the inactivation of isoniazid. Caffeine, which is also biotransformed by N-acetylation, has been widely used as an in vivo probe for the assessment of N-acetyltransferase polymorphism. The activity of N-acctyltransferase can be estimated from the urinary metabolic ratio of two caffeine metabolites, namely, 5-acetylamino-6-formy-lamino-3-methyluracil (AFMU), and 1-methylxanthine (1X) after the ingestion of caffeine. In the present study caffeine was used as a metabolic probe to determine N-acetyltransferase polymorpism in 83 healthy Creek volunteers by means of the molar ratio of AFMU and 1X determined in urine following ingestion of 200 mg caffeine. Frequency distribution analysis of the metabolic ratios AFMU/1X revealed two distinct groups with 66.3% (n = 55) slow acetylators and 33.7 % (n = 28) rapid acetylators. No statistically significant difference was detected between slow and fast acetylators in terms of gender, smoking habits and caffeine-intake habits. These results are in agreement with previous studies on N-acetyltransferase activity in Caucasians using caffeine as a metabolic probe. They also agree with reports on N-acetyltransferase activity in Greek tuberculosis patients using isoniazid as a metabolic probe. Thus, the use of caffeine as a metabolic probe is a reliable method for the assessment of N-acetyltransferase activity in the Greek population.
引用
收藏
页码:501 / 506
页数:6
相关论文
共 31 条
[1]  
[Anonymous], 1990, DESIGN EXPT
[2]   HUMAN ARYLAMINE N-ACETYLTRANSFERASE GENES - ISOLATION, CHROMOSOMAL LOCALIZATION, AND FUNCTIONAL EXPRESSION [J].
BLUM, M ;
GRANT, DM ;
MCBRIDE, W ;
HEIM, M ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1990, 9 (03) :193-203
[3]   N-ACETYLATION PHARMACOGENETICS - A GENE DELETION CAUSES ABSENCE OF ARYLAMINE N-ACETYLTRANSFERASE IN LIVER OF SLOW ACETYLATOR RABBITS [J].
BLUM, M ;
GRANT, DM ;
DEMIERRE, A ;
MEYER, UA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (23) :9554-9557
[4]   A URINARY METABOLITE RATIO THAT REFLECTS SYSTEMIC CAFFEINE CLEARANCE [J].
CAMPBELL, ME ;
SPIELBERG, SP ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (02) :157-165
[5]  
CASCORBI I, 1995, AM J HUM GENET, V57, P581
[6]   THE HEALTH CONSEQUENCES OF CAFFEINE [J].
CURATOLO, PW ;
ROBERTSON, D .
ANNALS OF INTERNAL MEDICINE, 1983, 98 (05) :641-653
[7]   PHARMACOKINETICS OF ISONIAZID METABOLISM IN MAN [J].
ELLARD, GA ;
GAMMON, PT .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1976, 4 (02) :83-113
[8]   GENETIC CONTROL OF ISONIAZID METABOLISM IN MAN [J].
EVANS, DAP ;
MANLEY, KA ;
MCKUSICK, VA .
BRITISH MEDICAL JOURNAL, 1960, 2 (AUG13) :485-491
[9]   PREDICTION OF PHENOTYPE FOR ACETYLATION AND FOR DEBRISOQUINE HYDROXYLATION BY DNA-TESTS IN HEALTHY-HUMAN VOLUNTEERS [J].
GRAF, T ;
BROLY, F ;
HOFFMANN, F ;
PROBST, M ;
MEYER, UA ;
HOWALD, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) :399-403
[10]   VARIABILITY IN CAFFEINE METABOLISM [J].
GRANT, DM ;
TANG, BK ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (05) :591-602